IKTHealthcare · BiotechnologyThe 10 Wall Street analysts covering Inhibikase Therapeutics, Inc. hold a median 12-month price target of $5.5 — +239.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Inhibikase Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (73): The shares have been drifting up relative to others.
Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on IKT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +239.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | Chardan Capital | Initiates | Neutral | $1.50 |
| 10 June 2026 | Oppenheimer | Initiates | Outperform | — |
| 4 Mar 2026 | Ladenburg Thalmann | Initiates | Buy | — |
| 21 Jan 2026 | B of A Securities | Initiates | Buy | — |
| 26 Dec 2025 | HC Wainwright & Co. | Assumes | Buy | $8.00 |
| 17 Dec 2025 | Freedom Broker | Initiates | Buy | — |
| 11 Dec 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 28 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 12 Feb 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 8 Nov 2024 | Jefferies | Initiates | Buy | — |
| 14 Oct 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 21 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 June 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 June 2023 | HC Wainwright & Co. | Reiterates | Buy | $5.00 |
| 18 Apr 2023 | HC Wainwright & Co. | Initiates | Buy | $5.00 |
| 16 Nov 2022 | JonesTrading | Downgrade | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IKT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Inhibikase Therapeutics, Inc. returned +10.2% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 67% of US stocks
Cheaper than 47% of US stocks
Cheaper than 73% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 21% of US stocks
Higher than 13% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Inhibikase Therapeutics, Inc. has a market value of $219.1M and an enterprise value of $126.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$60.6M.
Trailing P/E: 3.6×; forward P/E: −3.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Inhibikase Therapeutics, Inc. employs 35 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Inhibikase Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Inhibikase Therapeutics announced that its management will participate in investor conferences during November and December 2026. The company develops IKT-001, a once-daily oral candidate for pulmonary arterial hypertension.
Why it matters — The announcement provides IKT watchers with information about upcoming opportunities to hear from company management.
Inhibikase Therapeutics announced the appointment of Scott Wasserman to its Board of Directors. The company is developing IKT-001, a once-daily oral anti-proliferative for pulmonary arterial hypertension.
Why it matters — The appointment is a corporate governance update for investors following Inhibikase.
Inhibikase Therapeutics announced it granted non-qualified stock options to purchase up to an aggregate of 128,000 shares of common stock to two newly-hired non-executive employees under its 2026 Inducement Equity Plan, effective September 30, 2026. The grants were approved by the Compensation Committee as a material inducement to the employees' entry into employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters — IKT watchers would care because this discloses new shareholder-dilutive equity compensation tied to recent hires, and confirms the company is expanding headcount under its inducement plan.
Inhibikase Therapeutics reported its financial results for the quarter ended June 30, 2026, and highlighted recent developments. The company, which is developing IKT-001 for Pulmonary Arterial Hypertension, announced these results via GlobeNewsWire on August 11, 2026.
Why it matters — IKT watchers would care because the quarterly financial results and recent activity update offer insight into the company's progress and cash position as it advances its PAH clinical program.
The 10 Wall Street analysts covering Inhibikase Therapeutics, Inc. have a median 12-month price target of $5.5, with estimates ranging from $1.5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Inhibikase Therapeutics, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Inhibikase Therapeutics, Inc. 36 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Inhibikase Therapeutics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (73 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +239.5% from the last close, and Ticker Nerd's factor model ranks Inhibikase Therapeutics, Inc. 36 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Inhibikase Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IKT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $8 over the next 12 months.
Inhibikase Therapeutics, Inc. returned +10.2% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing protein kinase inhibitor therapies for cardiopulmonary and neurodegenerative diseases.
The most recent item we track (GlobeNewsWire, 27 Oct 2026): "Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026". Inhibikase Therapeutics announced that its management will participate in investor conferences during November and December 2026. The company develops IKT-001, a once-daily oral candidate for pulmonary arterial hypertension.
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing protein kinase inhibitor therapies for cardiopulmonary and neurodegenerative diseases. Its current portfolio is centered on pulmonary arterial hypertension, where it is advancing an oral prodrug of imatinib mesylate designed to address disease pathways linked to abnormal kinase signaling. The company also maintains a neuroscience-oriented program targeting Parkinson’s disease and related disorders through Abelson tyrosine kinase inhibition. Inhibikase Therapeutics works across areas of rare disease, cardiopulmonary medicine, and neurology, with a business model built around small-molecule drug development and clinical research. Headquartered in Wilmington, Delaware, Inhibikase Therapeutics plays a specialized role in the biopharmaceutical market by pursuing therapies for conditions with limited treatment options and significant unmet medical need.
CEO Mr. Mark T. Iwicki · 35 employees · United States · https://www.inhibikase.com
